NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial) |
|
|
| Active, not recruiting | 2 | 234 | US | Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide | Dana-Farber Cancer Institute, Bayer, Decipher Biosciences | Prostate Cancer | 03/25 | 03/28 | | |
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer |
|
|
| Recruiting | 1/2 | 596 | US | BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation) | ImmunityBio, Inc. | Non-muscle Invasive Bladder Cancer | 12/28 | 12/38 | | |